PT  - JOURNAL ARTICLE
AU  - Ray, Joel G
AU  - Park, Alison L
TI  - SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study
AID  - 10.1136/bmjopen-2021-059944
DP  - 2022 Jul 01
TA  - BMJ Open
PG  - e059944
VI  - 12
IP  - 7
4099  - http://bmjopen.bmj.com/content/12/7/e059944.short
4100  - http://bmjopen.bmj.com/content/12/7/e059944.full
SO  - BMJ Open2022 Jul 01; 12
AB  - Objective To compare outcomes between O and non-O blood groups, and by modified RNA (mRNA) and adenovirus-vectored (Ad-V) vaccines.Design Population-based cohort study.Setting All of Ontario, Canada. Linked data sets captured clinical encounters, vaccinations and laboratory testing for SARS-CoV-2.Participants Individuals aged 12+ years with known ABO blood group and free of SARS-CoV-2 before 15 January 2021.Main outcomes measures The main exposure, first SARS-CoV-2 vaccination, was modelled in a time-varying manner. O and non-O blood group was known prior to vaccination. SARS-CoV-2 infection, and severe COVID-19 (hospitalisation or death), were assessed starting 14 days after vaccination, up to 27 June 2021.Results 2 472 261 individuals were included. 1 743 916 (70.5%) had at least one vaccination, of which 24.6% were fully vaccinated. Those vaccinated were more likely to be women, older in age, residing in a higher-income area and have higher rates of certain comorbid conditions, like cancer, diabetes and hypertension. Relative to unvaccinated, after receiving their first mRNA (adjusted HR (aHR) 0.46, 95% CI 0.44 to 0.47) or Ad-V (aHR 0.49, 95% CI 0.44 to 0.54) vaccine, the risk of SARS-CoV-2 infection was lower, as was severe COVID-19 (aHR 0.29, 95% CI 0.20 to 0.43 (mRNA); aHR 0.29, 95% CI 0.26 to 0.33 (Ad-V)). Stratifying by blood group produced similar results. For example, after first mRNA vaccination, the aHR of severe COVID-19 was 0.31 (95% CI 0.27 to 0.36) among non-O blood groups, and 0.27 (95% CI 0.22 to 0.32) among O blood groups, relative to unvaccinated. Fully vaccinated individuals had the lowest risk of SARS-CoV-2 and severe COVID-19.Conclusions SARS-CoV-2 infection and severe COVID-19 are reduced by vaccination. This effect does not vary by vaccine type or blood group, but is more pronounced among fully, than partially, vaccinated individuals.No data are available. No additional data available.